3M PFAS Settlement: $5.8B for 120,000 Injury Claims

3M's PFAS personal-injury settlement works out to $61,000 to $64,000 per claimant across the 115,000 to 120,000 plaintiffs the company says are eligible (3M press release, November 3, 2026). At the $5.8 billion present value 3M will book, it is $48,000 to $50,000. Either way it is about a third of the roughly $190,000 a claimant that DuPont and Chemours paid to close the C8 personal-injury docket in 2017.

3M signed the master settlement agreement on November 3 with the plaintiffs' negotiating counsel in the AFFF multidistrict litigation before Judge Richard Gergel in South Carolina. It was filed the same day as Exhibit 10.1 to a Form 8-K, with the payment schedule as Exhibit 10.1A. 3M will record a pre-tax charge of about $5.8 billion in the fourth quarter as a special item outside adjusted earnings.

Signing came a year after the court pulled the first personal-injury bellwether trial, a kidney cancer case set for October 2025, to vet a wave of unfiled claims. A docket page maintained by the court counts more than 23,000 cases and about 100,000 plaintiffs since the MDL was formed in 2018.

Key Takeaways

Each eligible claimant is priced at about $61,000 to $64,000 nominal, or $48,000 to $50,000 at the present value 3M will book.
Back-loaded payments imply a discount rate near 6% a year, a 21% haircut a US casualty insurer cannot take on a statutory reserve.
A $680 million reserve fund, 9.3% of the commitment, is the first manufacturer-sized price on PFAS injury claims not yet filed.
3M can terminate if participation misses confidential thresholds, so the commitment stays a range until the administrator counts enrollments in about a year.
Per claimant, the deal is a third of the roughly $190,000 DuPont and Chemours paid to settle about 3,500 C8 cases in 2017.

What the $7.35 Billion Buys

Five pieces make up the commitment. Six main installments of $1.045 billion each, due between January 2028 and July 2033, make up $6.27 billion. A $50 million initial payment funds the qualified settlement fund within 30 days and covers administration costs. Two participation-threshold payments of $125 million and two bonus payments of $50 million depend on enrollment rates set in a confidential exhibit. A $680 million reserve fund, paid in six installments from 2029 to 2034, is the remainder (3M Form 8-K Exhibit 10.1A, November 3, 2026).

Year	Scheduled payments ($M)	Components
2026	50	Initial settlement payment
2027	0	No payment
2028	1,045	Main installment 1 (not before January 15)
2029	1,204	Main installment 2; $125M threshold payment; $34M reserve fund
2030	1,238	Main installment 3; $125M threshold payment; $68M reserve fund
2031	1,163	Main installment 4; $68M reserve fund; $50M bonus
2032	1,163	Main installment 5; $68M reserve fund; $50M bonus
2033	1,147	Main installment 6; $102M reserve fund
2034	340	Final reserve fund payment
Total	7,350	Assumes every contingent payment is made

Source: 3M Form 8-K Exhibit 10.1A, November 3, 2026, summed by the site by earliest payment year. Payments in the last two years total $1.487 billion, 20.2% of the whole, which 3M said matches the timing of its other legacy settlements.

Every payment after the first $50 million is contingent on neither side exercising its termination right. Under the agreement, 3M holds the right "in its sole discretion, to terminate the Settlement Agreement" if the conditions in Confidential Exhibit 12 are met. If that happens, any unspent initial payment, plus interest, "shall be returned to 3M." Two participation rates drive those conditions: an overall rate across all eligible claimants and a specific rate for claimants with kidney or testicular cancer.

Eligibility covers six diagnoses: kidney cancer, testicular cancer, liver cancer, thyroid cancer, ulcerative colitis and thyroid disease. Each participating claimant receives a point score from diagnosis and exposure route, drinking water or direct contact. Awards are that score multiplied by a dollar-per-point value set once enrollment is known.

Chief executive William Brown told investors on November 4 that the court's fact-sheet process, which required every plaintiff to document a qualifying claim, produced the 115,000 to 120,000 eligible count (Manufacturing Dive, November 4, 2026).

Against that count, $7.35 billion divides to $61,250 at 120,000 claimants and $63,900 at 115,000. Strip out the $680 million reserve fund and the figure for current claimants falls to $55,600 to $58,000.

C8 is the nearest precedent. DuPont and Chemours paid $670.7 million in cash, $335.35 million each, to close about 3,500 personal-injury cases in the Ohio MDL (Chemours Form 8-K, February 2017). That was about $190,000 a claim, paid at once. In June, the site's analysis of PFAS reserving worked from projections of $200,000 to $600,000 per cancer claimant. This blended figure lands below that range because the eligible pool is more than thirty times the C8 docket and takes in thyroid disease and ulcerative colitis alongside cancers.

Two Values for One Liability

Schedule timing produces the $1.55 billion gap between the nominal and present-value figures. Discounting the Exhibit 10.1A dates back to November 3, 2026, the site's arithmetic lands on a rate near 6% a year if every contingent payment is made. On a dollar-weighted basis the average payment falls a little over four years out. By comparison, the 2023 public water supplier settlement was discounted from $12.5 billion nominal to $10.3 billion, a 17.6% haircut against 21.1% here (3M Form 8-K, June 22, 2023). That schedule carried $4.8 billion in its first three years.

3M will carry the $5.8 billion and accrete interest on it through 2034. Its third-quarter Form 10-Q already records imputed interest on the water supplier, New Jersey and earplug settlement obligations. A US casualty insurer facing the same claims holds the opposite book: SSAP No. 55 carries its loss reserves undiscounted, so Schedule P shows the full nominal amount as incurred on the day a settlement is booked.

A reinsurer pricing an adverse development cover on a book with PFAS bodily-injury exposure prices the undiscounted equivalent of $7.35 billion. Markel bought that structure from Enstar last week on $4.8 billion of legacy reserves. 3M's $5.8 billion is 79 cents on that dollar.

The $680 Million Tail

Six installments from April 2029 to April 2034 fund the reserve, rising from $34 million to a final $340 million, and the agreement caps it at "no more than $680,000,000." Funding is conditioned on the MDL and CMO 40 continuing, the order the agreement identifies as governing non-settling plaintiffs.

3M's release lists the fund among the mechanisms for "remaining and future" personal-injury claims (3M press release, November 3, 2026). Beside it sits an anticipated court order "establishing evidentiary and timing requirements" for plaintiffs who litigate later.

Setting aside 9.3% of the commitment for claims not yet filed is the first manufacturer-sized price on the PFAS latency tail. A general liability or products actuary now has a manufacturer's ratio of unfiled to filed claims, 9.3 cents per dollar, on a vetted base. Chemours' consent decree in June priced only remediation and water-supply components.

Who pays the $7.35 billion remains unsettled on the insurance side. Anurag Maheshwari, 3M's chief financial officer, told the November 4 call that free cash flow, capital markets access and insurance recoveries "give us confidence in meeting the obligations under this agreement" (Manufacturing Dive, November 4, 2026). AIG sued 3M in October 2024 for a ruling that its policies limit or bar coverage for PFAS liability. 3M said it "strongly opposes its insurance companies' attempts to avoid their coverage obligations for PFAS claims" (Fox 9, January 2025).

For an excess carrier or reinsurer, a $61,000 average claim sits far below any per-occurrence attachment, while 120,000 of them aggregate to $7.35 billion. Whether that is one occurrence, six, or 120,000 is the batch-clause question a PFAS reserve turns on, the same allocation fight the site covered when an Arkansas court ordered Walmart's insurers to defend 2,400 opioid suits.

Coverage rulings so far split along the settlement's own exposure line. In National Foam v. Zurich (N.D. Cal., February 2025) the pollution exclusion barred claims alleging indirect environmental exposure. It left a duty to defend a claim of direct exposure through product use (Simpson Thacher, November 2025).

3M's first $1.045 billion installment is not due before January 15, 2028, and only if neither side has exercised its termination right by then.

3M Books $5.8B to Settle 120,000 PFAS Injury Claims for $7.35B

Key Takeaways

What the $7.35 Billion Buys

Two Values for One Liability

The $680 Million Tail

Further Reading

Sources

3M Books $5.8B to Settle 120,000 PFAS Injury Claims for $7.35B

Key Takeaways

What the $7.35 Billion Buys

Two Values for One Liability

The $680 Million Tail

Further Reading

Related guides

Sources